SEROBA/KURMA-PARTNERS
24.6.2024 08:01:25 CEST | Business Wire | Press release
Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, based in Paris and Munich, announced today the completion of the second closing part of Series B financing round of Vico Therapeutics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240623484065/en/
Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing therapies for severe neurological diseases. Its lead program VO659 is currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease, devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available.
Seroba joined the consortium of investors leading the planned second closing of the Series B financing round of an additional €11.5 million ($12.4 million) with participation from Kurma Growth Opportunities Fund supporting Vico to continue to advance their lead clinical program and further develop a portfolio of novel antisense oligonucleotides. Existing investors include Ackermans & van Haaren (AvH), Droia Ventures, EQT Life Sciences, Eurazeo, Kurma Biofund, Polaris Partners and Pureos Bioventures, for a total Series B financing round of €65.8 million ($70.7 million).
Catello Somma, Partner at Seroba, commented:
“We are extremely proud to support Vico in this financing round and join the existing investors. The growth capital will help the Company to bolster its clinical programs to deliver life-changing outcomes for patients with polyQ diseases, such as SCA and Huntington's. We are excited to partner with Vico and its remarkable team as the Company advances its programs.”
Daniel Parera and Jean-Francois Rivassou, Partners at Kurma, commented:
“Vico is another very nice example of a company where Kurma Partners acted as a co-founding investor (Rémi Droller on behalf of Kurma Biofund III alongside with EQT Life Sciences) that has progressed into clinical development, where Kurma Growth Opportunities Fund is able to add further support to the Company and its experienced management team in the continuation of Vico’s path together with existing investors.”
About Seroba.
Seroba is a European life sciences venture capital firm based in Dublin, Paris and Milan, investing from its fourth Fund. Seroba focuses on value creation through backing cutting-edge biotech and medtech innovation that will transform the treatment of patients, addressing unmet medical needs. The Seroba team has deep industry, operational and investing experience and an extensive global network. Seroba likes to work with entrepreneurs who share its passion for success and with investors who share the same goal of improving human health while driving financial returns.
Follow Seroba’s story at https://serobavc.com/
About Kurma Partners
Founded in July 2009 and based in Paris and Munich, Kurma Partners is a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital. Kurma invests through its funds Kurma Biofund I, II and III, Kurma Diagnostics and Kurma Diagnostics 2, and the most recent Kurma Growth Opportunities Fund, for which this is the eighth investment. Kurma collaborates through extensive networks of prestigious research and academic institutes, premier cluster organizations and hospitals connecting with established industry players. Kurma Partners is part of the Eurazeo Group.
www.kurmapartners.com (www.eurazeo.com/en)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240623484065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Introduces Maestro Agent Studio, Unlocking Next Level Decision Making Through Composable AI Agents5.2.2026 13:01:00 CET | Press release
These composable AI agents reflect how supply chains actually operate Kinaxis® Inc. (TSX: KXS), the leader in supply chain orchestration, today announced Maestro Agent Studio, making the next phase of its AI agent strategy available to customers following the launch of prebuilt Maestro Agents. Maestro Agent Studio gives supply chain teams a no-code way to compose AI agents grounded in their real operating context, using the same data, workflows, and tools planners already rely on, so agents drive real-world outcomes. Built into the Kinaxis Maestro® platform, Maestro Agent Studio enables supply chain teams and leaders to apply their expertise across every day and high-impact supply chain decisions without relying on manual, repetitive tasks or custom code development. Maestro Agent Studio is designed to work with leading large language models, including OpenAI’s GPT and Google Gemini, while keeping agent behavior anchored in Maestro’s trusted data, intelligence, and governance. The real
Introducing RAVE Aerospace: A New Name, Built on a Legacy of In-Flight Innovation5.2.2026 13:00:00 CET | Press release
Kingswood Capital Management completes acquisition of Safran Passenger Innovations and unveils the new RAVE Aerospace name, reflecting the company’s strong heritage of innovation and positioning it for the next phase of growth For nearly two decades, RAVE has been a trusted name in in-flight entertainment and connectivity for customers around the world. Today, that heritage continues under a new company name: RAVE Aerospace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205748681/en/ Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) has completed its acquisition of Safran Passenger Innovations (“SPI”), a leading global provider of in-flight entertainment and connectivity solutions, from Safran, an international aerospace group. As part of the transaction, SPI has been renamed as RAVE Aerospace, which will continue to build on the established RAVE brand that has powered in-flight entertainment a
Menicon’s Largest Malaysia Plant Begins Commercial Production5.2.2026 10:00:00 CET | Press release
- Strengthening Global Production Capacity for the Rapidly Growing 1-Day Lens Market Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, uncompromising quality, and a stable global supply of contact lenses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127294120/en/ The newly opened Malaysia plant is Menicon’s largest site to date and is dedicated exclusively to producing 1-DAY lenses. As global demand for 1-DAY lenses continues rising and the industry faces widespread supply constraints, Menicon has made significant capital investments to expand production capacity—even amid the uncertainties presented by the COVID-19 pandemic. Construction of phase 1, currently underway, will provide capacity for up to 500 million lenses per year. The construction plan i
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 09:00:00 CET | Press release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom